{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Giacobbe DR"],"funding":["Pfizer Global Medical Grants"],"pagination":["dlaf177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12498522"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(5)"],"pubmed_abstract":["<h4>Objectives</h4>In this multicentre, prospective study, we aimed to describe the use of isavuconazole in critically ill adult patients in ICU, in terms of patient characteristics, infection characteristics and outcomes.<h4>Methods</h4>Prospective, observational study of ICU patients treated with isavuconazole from January 2023 to 30 April 2025 in 17 centres (ISA-SITA study within the MULTI-SITA project).<h4>Results</h4>A total of 177 ICU patients treated with isavuconazole were included in the study. Most patients showed at least one European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) or FUNgal Diseases in adult patients in Intensive Care Unit (FUNDICU) host factor (141/177, 79.7%). Overall, 82/177 patients (46."],"journal":["JAC-antimicrobial resistance"],"pubmed_title":["Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study."],"pmcid":["PMC12498522"],"funding_grant_id":["73582567"],"pubmed_authors":["De Benedetto I","Marchese A","Albertini M","Angelini J","Rinaldi M","Giuliano S","Pallone R","Cacopardo B","Battaglini D","Caroli A","Russo A","Livanu D","Costarella D","Piana M","Casarini M","Serapide F","Bruni A","Pinna SM","De Pascale G","Bassetti M","Merli M","Ricciardetto M","Simoncini E","Giacobbe DR","Portunato F","De Rosa FG","Mengato D","Fanelli C","Franzo A","Di Pilato V","Del Bono V","Giannella M","Aldieri C","Moreal C","Pontali E","Del Puente F","Di Meco G","Gallone S","Viale P","Chemello D","Navalesi P","Briano F","Di Biagio A","Garofalo E","Santoro A","Tiberio I","Cappello A","Bavastro M","Fava F","Longhini F","Marino A","Muccio M","Bono E","Robba C","Torti C","Losito AR","Shbaklo N","Martini L","Patroniti N","Gullotta C","Bartalucci C","Giacomini M","Flammini S","Murgia Y","Campanella EA","Panese S","Cammarota F","Ball L","D'amico F","Maida I","Antola S","Munari M","Guastavino S","Asperges E","Mazzitelli M","Lamarina A","Franceschini E","Magnasco L","Sanguinetti M","Blasi Vacca E","Travi G","Geremia N","Coppo E","Cattelan A","Meschiari M","ISA-SITA investigators","Musso S","Cosentino F","Ferin S","Boffa N","Mora S","Scaglione V","Vena A","Montanari L","Mikulska M","Viglietti G","Schiavoni R","Lupia T","Rosso N","Boni S","Meloni MC","Calabresi A","Campi C","Oltolini C","Signori A","Serino FS","Momesso E","Sassi S","Corcione S","Tigano S"],"additional_accession":[]},"is_claimable":false,"name":"Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study.","description":"<h4>Objectives</h4>In this multicentre, prospective study, we aimed to describe the use of isavuconazole in critically ill adult patients in ICU, in terms of patient characteristics, infection characteristics and outcomes.<h4>Methods</h4>Prospective, observational study of ICU patients treated with isavuconazole from January 2023 to 30 April 2025 in 17 centres (ISA-SITA study within the MULTI-SITA project).<h4>Results</h4>A total of 177 ICU patients treated with isavuconazole were included in the study. Most patients showed at least one European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) or FUNgal Diseases in adult patients in Intensive Care Unit (FUNDICU) host factor (141/177, 79.7%). Overall, 82/177 patients (46.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T06:55:31.649Z","creation":"2026-05-06T03:12:39.591Z"},"accession":"S-EPMC12498522","cross_references":{"pubmed":["41059267"],"doi":["10.1093/jacamr/dlaf177"]}}